Pancreatic Cancer Research

ResearcherNational Institute of Public HealthActive in the last 2 years

Yuki Takumoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9191-3494; OpenAlex author ID A5086507106. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers

Papers 8

  1. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Co-author DOI 10.1002/cam4.71161↗
  2. Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. First author DOI 10.1002/cam4.71233↗
  3. Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data. First author DOI 10.1038/s41598-024-80549-1↗
  4. Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. First author DOI 10.3389/frhs.2024.1275496↗
  5. Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study. Co-author DOI 10.1002/cam4.6100↗
  6. Correction: Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. Co-author DOI 10.1186/s13561-023-00418-x↗
  7. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysi… Co-author DOI 10.1001/jamanetworkopen.2021.45515↗
  8. Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. Co-author DOI 10.1186/s13561-022-00413-8↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Manabu Akazawa · 8 shared papers, 2022–2025 · strength 1.97
  2. Yuriko Sasahara · 5 shared papers, 2022–2025 · strength 1.18
  3. Hiroto Narimatsu · 3 shared papers, 2022–2025 · strength 0.74
  4. Makoto Ueno · 2 shared papers, 2024–2025 · strength 0.41
  5. Akira Shinohara · 1 shared paper, 2025 · strength 0.30
  6. Kenji Ikezawa · 1 shared paper, 2025 · strength 0.22
  7. Takeshi Terashima · 1 shared paper, 2025 · strength 0.22
  8. Masafumi Ikeda · 1 shared paper, 2025 · strength 0.22
  9. Naohiro Okano · 1 shared paper, 2025 · strength 0.22
  10. Masato Ozaka · 1 shared paper, 2025 · strength 0.22
  11. Akihiro Ohba · 1 shared paper, 2025 · strength 0.22
  12. Junji Furuse · 1 shared paper, 2025 · strength 0.22
  13. Takuji Okusaka · 1 shared paper, 2025 · strength 0.22
  14. Chigusa Morizane · 1 shared paper, 2025 · strength 0.22
  15. Takashi Yoshioka · 1 shared paper, 2024 · strength 0.19
  16. Kumiko Umemoto · 1 shared paper, 2024 · strength 0.19
  17. Hiroyuki Takeda · 1 shared paper, 2024 · strength 0.19
  18. Yu Sunakawa · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.